SG10201909199PA - Method for treating cancer - Google Patents
Method for treating cancerInfo
- Publication number
- SG10201909199PA SG10201909199PA SG10201909199PA SG10201909199PA SG 10201909199P A SG10201909199P A SG 10201909199PA SG 10201909199P A SG10201909199P A SG 10201909199PA SG 10201909199P A SG10201909199P A SG 10201909199PA
- Authority
- SG
- Singapore
- Prior art keywords
- treating cancer
- inhibitor
- ezh2
- bstract
- present disclosure
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562209304P | 2015-08-24 | 2015-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201909199PA true SG10201909199PA (en) | 2019-11-28 |
Family
ID=58100964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201909199P SG10201909199PA (en) | 2015-08-24 | 2016-08-24 | Method for treating cancer |
Country Status (12)
Country | Link |
---|---|
US (4) | US10493076B2 (ja) |
EP (1) | EP3341080A4 (ja) |
JP (1) | JP2018525414A (ja) |
KR (1) | KR20180042356A (ja) |
CN (1) | CN108025191A (ja) |
AU (2) | AU2016312514A1 (ja) |
CA (1) | CA2996412A1 (ja) |
EA (1) | EA201890567A1 (ja) |
IL (2) | IL307260A (ja) |
MX (1) | MX2018002344A (ja) |
SG (1) | SG10201909199PA (ja) |
WO (1) | WO2017035234A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012135160A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
KR20180054793A (ko) * | 2015-09-25 | 2018-05-24 | 에피자임, 인코포레이티드 | 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법 |
CA3011186A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
EP3464643A4 (en) | 2016-06-01 | 2020-04-01 | Epizyme Inc | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER |
US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
MX2019013862A (es) | 2017-05-23 | 2020-01-20 | Mei Pharma Inc | Terapia de combinacion. |
JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム,インコーポレイティド | 癌を処置するためのezh2阻害剤の使用 |
CA3072476A1 (en) | 2017-08-14 | 2019-02-21 | Mei Pharma, Inc. | Combination therapy |
CN111093660A (zh) | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
EP3836935A4 (en) * | 2018-08-14 | 2022-09-14 | MEI Pharma, Inc. | TREATMENT OF B-CELL MALIGNOS |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5455044A (en) | 1993-05-14 | 1995-10-03 | Depotech Corporation | Method for treating neurological disorders |
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
EP2238982B8 (en) | 2003-06-27 | 2013-01-16 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
US20120114670A1 (en) | 2007-10-02 | 2012-05-10 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
WO2009048958A2 (en) | 2007-10-08 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
EP2566479B1 (en) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Azaindazoles |
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
WO2012071096A2 (en) | 2010-09-03 | 2012-05-31 | The Johns Hopkins University | Arid1a and ppp2r1a mutations in cancer |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012075080A1 (en) | 2010-12-01 | 2012-06-07 | Glaxosmithkline Llc | Indoles |
EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
CN103619337A (zh) | 2011-05-16 | 2014-03-05 | 乌尔里克·努伯 | 新型癌症疗法和方法 |
EP2755962B1 (en) | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
CN103987842A (zh) | 2011-09-30 | 2014-08-13 | 葛兰素史密斯克莱有限责任公司 | 治疗癌症的方法 |
WO2013059944A1 (en) | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2014124418A1 (en) | 2013-02-11 | 2014-08-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2825161B1 (en) * | 2012-03-12 | 2019-01-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
EP2828250B1 (en) | 2012-03-19 | 2021-03-10 | Imperial College Innovations Limited | Quinazoline compounds and their use in therapy |
CN104768555B (zh) | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
LT3184523T (lt) | 2012-04-13 | 2020-02-10 | Epizyme Inc | N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
RU2018145311A (ru) | 2012-10-15 | 2019-02-18 | Эпизайм, Инк. | Способы лечения рака |
TWI588131B (zh) | 2012-10-15 | 2017-06-21 | 雅酶股份有限公司 | 經取代苯化合物 |
US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2014092905A1 (en) | 2012-12-10 | 2014-06-19 | Children's Medical Center Corporation | Methods and assays for combination treatment of cancer |
CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
WO2014144747A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
WO2014176047A1 (en) | 2013-04-25 | 2014-10-30 | Novartis Ag | Markers for ezh2 inhibitors |
CN105308038B (zh) | 2013-04-30 | 2018-05-29 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2的抑制剂 |
WO2014195919A1 (en) | 2013-06-06 | 2014-12-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
EP3019494B1 (en) | 2013-07-10 | 2017-06-21 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
PL3057962T3 (pl) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Postać soli chlorowodorku do inhibicji ezh2 |
US20160228447A1 (en) | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
US20160303135A1 (en) | 2013-12-06 | 2016-10-20 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2015103431A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
AU2015225775B2 (en) | 2014-03-07 | 2017-06-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
KR20230031963A (ko) | 2014-06-17 | 2023-03-07 | 에피자임, 인코포레이티드 | 림프종 치료를 위한 ezh2 억제제 |
ES2870096T3 (es) | 2014-06-19 | 2021-10-26 | Memorial Sloan Kettering Cancer Center | Biomarcadores de respuesta a los inhibidores de EZH2 |
US20170217941A1 (en) | 2014-06-25 | 2017-08-03 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
EP3189036B1 (en) | 2014-09-05 | 2023-07-19 | ArQule, Inc. | Compositions and methods for treating proliferation disorders |
BR112017007738B1 (pt) | 2014-10-16 | 2023-04-11 | Epizyme, Inc | Método para determinar a probabilidade de eficácia de um tratamento e método para triagem da eficácia de um tratamento compreendendo um inibidor de ezh2 |
CN116650500A (zh) | 2014-11-17 | 2023-08-29 | Epizyme股份有限公司 | 治疗癌症的方法 |
JP2018513865A (ja) | 2015-04-20 | 2018-05-31 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
CA2988816A1 (en) | 2015-06-10 | 2016-12-15 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
US10493076B2 (en) * | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
KR20180054793A (ko) | 2015-09-25 | 2018-05-24 | 에피자임, 인코포레이티드 | 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법 |
CA3000983A1 (en) | 2015-10-06 | 2017-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Method of treating medulloblastoma with an ezh2 inhibitor |
US20190070188A1 (en) | 2015-11-06 | 2019-03-07 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
US20210052595A1 (en) | 2015-12-07 | 2021-02-25 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
CA3011186A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2017139404A1 (en) | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
US20200129519A1 (en) | 2016-06-08 | 2020-04-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
JP7324144B2 (ja) | 2017-02-02 | 2023-08-09 | エピザイム,インコーポレイティド | 癌処置様式 |
-
2016
- 2016-08-24 US US15/754,684 patent/US10493076B2/en active Active
- 2016-08-24 AU AU2016312514A patent/AU2016312514A1/en not_active Abandoned
- 2016-08-24 EA EA201890567A patent/EA201890567A1/ru unknown
- 2016-08-24 WO PCT/US2016/048401 patent/WO2017035234A1/en active Application Filing
- 2016-08-24 SG SG10201909199P patent/SG10201909199PA/en unknown
- 2016-08-24 CN CN201680054668.1A patent/CN108025191A/zh active Pending
- 2016-08-24 JP JP2018510124A patent/JP2018525414A/ja active Pending
- 2016-08-24 MX MX2018002344A patent/MX2018002344A/es unknown
- 2016-08-24 EP EP16840037.2A patent/EP3341080A4/en not_active Withdrawn
- 2016-08-24 KR KR1020187007901A patent/KR20180042356A/ko not_active Application Discontinuation
- 2016-08-24 IL IL307260A patent/IL307260A/en unknown
- 2016-08-24 CA CA2996412A patent/CA2996412A1/en not_active Abandoned
-
2018
- 2018-02-22 IL IL257691A patent/IL257691A/en unknown
-
2019
- 2019-10-22 US US16/660,185 patent/US10898490B2/en active Active
-
2020
- 2020-12-21 US US17/128,634 patent/US11642349B2/en active Active
-
2022
- 2022-03-29 AU AU2022202118A patent/AU2022202118A1/en active Pending
-
2023
- 2023-03-23 US US18/188,706 patent/US20240024331A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200155561A1 (en) | 2020-05-21 |
US10493076B2 (en) | 2019-12-03 |
KR20180042356A (ko) | 2018-04-25 |
MX2018002344A (es) | 2018-07-06 |
AU2016312514A1 (en) | 2018-03-15 |
AU2022202118A1 (en) | 2022-04-14 |
CA2996412A1 (en) | 2017-03-02 |
US20180235975A1 (en) | 2018-08-23 |
WO2017035234A1 (en) | 2017-03-02 |
EA201890567A1 (ru) | 2018-08-31 |
JP2018525414A (ja) | 2018-09-06 |
US20210213027A1 (en) | 2021-07-15 |
IL307260A (en) | 2023-11-01 |
EP3341080A4 (en) | 2019-03-20 |
IL257691A (en) | 2018-04-30 |
EP3341080A1 (en) | 2018-07-04 |
US10898490B2 (en) | 2021-01-26 |
US11642349B2 (en) | 2023-05-09 |
US20240024331A1 (en) | 2024-01-25 |
CN108025191A (zh) | 2018-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006734A (es) | Metodo para tratar el cancer. | |
SG10201909199PA (en) | Method for treating cancer | |
EP4252851A3 (en) | Ezh2 inhibitors for treating lymphoma | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
WO2016025635A3 (en) | Combination therapy for treating cancer | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
MX2016017407A (es) | Inhibidores de histona demetilasa. | |
WO2016043874A3 (en) | Combination therapy for treating cancer | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
EP3538119A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN | |
AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
MX2017003466A (es) | Inhibidores de histona desmetilasa. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
EP3700551A4 (en) | TUMOR VACCIN COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OF CANCER | |
TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof |